Costing and Cost Analysis in Randomized Controlled Trials: Caveat Emptor

Author： Polsky Daniel   Glick Henry  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.27, Iss.3, 2009-01, pp. : 179-188

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

How Much is the Cost of Visual Impairment: Caveat Emptor

By Meads Catherine   Hyde Chris  

PharmacoEconomics, Vol. 24, Iss. 2, 2006-01 ,pp. : 207-209

Adis International

Access to resources Recommend Favorite

Ginseng for Alzheimer's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

By  

Current Topics in Medicinal Chemistry, Vol. 16, Iss. 5, 2016-02 ,pp. : 529-536

Bentham Science Publishers

Access to resources Recommend Favorite

External Surface Contamination of Cytotoxic Admixtures: Caveat Emptor

By  

JOURNAL OF PHARMACY PRACTICE AND RESEARCH, Vol. 41, Iss. 3, 2011-09 ,pp. : 181-182

John Wiley & Sons Inc

Access to resources Recommend Favorite

In Silico Studies in ADME/Tox: Caveat Emptor

By  

Current Computer - Aided Drug Design, Vol. 5, Iss. 2, 2009-06 ,pp. : 128-138

Bentham Science Publishers

Access to resources Recommend Favorite

The Efficacy of Acamprosate and Naltrexone in the Treatment of Alcohol Dependence: A Relative Benefits Analysis of Randomized Controlled Trials

By Snyder James   Bowers Thomas  

The American Journal of Drug and Alcohol Abuse, Vol. 34, Iss. 4, 2008-07 ,pp. : 449-461

Informa Healthcare

Access to resources Recommend Favorite